Toxicological Profile of the Pain-Relieving Antioxidant Compound Thioctic Acid in Its Racemic and Enantiomeric Forms.

antioxidant caspase-3 food supplement neuropathic pain thioctic acid

Journal

Antioxidants (Basel, Switzerland)
ISSN: 2076-3921
Titre abrégé: Antioxidants (Basel)
Pays: Switzerland
ID NLM: 101668981

Informations de publication

Date de publication:
14 Aug 2020
Historique:
received: 25 06 2020
revised: 04 08 2020
accepted: 11 08 2020
entrez: 23 8 2020
pubmed: 23 8 2020
medline: 23 8 2020
Statut: epublish

Résumé

Thioctic acid is a multipotent antioxidant compound existing as dextrorotatory (+), eutomer and naturally occurring and levorotatory (-). It has been proven to help fight many pathologies and is sold as racemate. In agreement with studies claiming a greater biopotency of the eutomer compared to the levorotatory compound, we recently preclinically and clinically showed that (+) thioctic acid is a pain-reliever as effective as double-dosed racemate. We investigated acute and subchronical toxicity of (+/-) thioctic acid, (-) thioctic acid, (+) thioctic acid and (+) salt thioctic acid on Sprague-Dawley rats. For acute toxicity, compounds were administered intraperitoneally (i.p.) with a single-injection at 125, 240, 360, 480 µmol/kg, then rodents were tested for motorial coordination and minimum lethal dose (LDmin). A subtoxic dose (360 µmol/kg) was administered i.p. for 15 days and we finally evaluated motorial impairment, glycemia, organ toxicity, and apoptosis state. Acutely administered, the highest doses of all thioctic acid compounds negatively affected motorial ability and (-) thioctic acid LDmin resulted higher than the others. Subchronic administrations caused overall body weight loss, motorial impairment, mass loss in some organs. (+/-) and (-) thioctic acid injections enhanced caspase-3 activity in some organs, (-) enantiomer-treated animals displayed more marked organ toxicity signs. Together with our previous study on the biologic role of enantiomers, these data suggest a therapeutic use of (+) enantiomer-based formulations, thus lowering dose and toxicity without affecting the positive effects brought by the drug.

Identifiants

pubmed: 32823851
pii: antiox9080749
doi: 10.3390/antiox9080749
pmc: PMC7464875
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Pharmacol Rep. 2011;63(4):849-58
pubmed: 22001972
J Biochem Mol Toxicol. 2017 Sep;31(9):
pubmed: 28598563
Diabetes Care. 1999 Aug;22(8):1296-301
pubmed: 10480774
J Hypertens. 2000 May;18(5):567-73
pubmed: 10826559
Diabetologia. 1995 Dec;38(12):1425-33
pubmed: 8786016
J Mol Model. 2012 Jul;18(7):2907-16
pubmed: 22127611
Exp Clin Endocrinol Diabetes. 1999;107(7):421-30
pubmed: 10595592
Toxicology. 2008 Jan 20;243(3):261-70
pubmed: 18068886
Free Radic Biol Med. 1995 Aug;19(2):227-50
pubmed: 7649494
Nutrition. 2001 Oct;17(10):888-95
pubmed: 11684397
Nutrients. 2019 Feb 12;11(2):
pubmed: 30759784
J Anim Physiol Anim Nutr (Berl). 2004 Apr;88(3-4):150-6
pubmed: 15059240
Biomed Res Int. 2013;2013:985093
pubmed: 24527432
Free Radic Biol Med. 2013 Aug;61:143-50
pubmed: 23548635
Neuropharmacology. 1996 Mar;35(3):369-75
pubmed: 8783212
J Inorg Biochem. 2018 Jul;184:19-26
pubmed: 29654931
Regul Toxicol Pharmacol. 2006 Oct;46(1):29-41
pubmed: 16904799
Regul Toxicol Pharmacol. 2006 Dec;46(3):193-201
pubmed: 16899332
J Lipid Res. 2010 Feb;51(2):352-9
pubmed: 19690335
J Neurosci. 2000 Feb 15;20(4):1333-41
pubmed: 10662823
Neuropharmacology. 1985 Mar;24(3):211-6
pubmed: 2986037
FASEB J. 2001 Mar;15(3):700-6
pubmed: 11259388
Biochim Biophys Acta. 2009 Oct;1790(10):1149-60
pubmed: 19664690
J Basic Clin Pharm. 2016 Mar;7(2):27-31
pubmed: 27057123
FASEB J. 2008 Mar;22(3):659-61
pubmed: 17942826
Inflamm Res. 2017 Nov;66(11):947-959
pubmed: 28676917
Diabetol Metab Syndr. 2014 Jul 28;6(1):80
pubmed: 25104975
Biomolecules. 2019 Aug 09;9(8):
pubmed: 31405030
Diabetes. 1996 Dec;45(12):1798-804
pubmed: 8922368
Diabetes Care. 2011 Sep;34(9):2054-60
pubmed: 21775755
J Biochem Mol Toxicol. 2020 Jul 8;:e22564
pubmed: 32640490
Clin Pharmacol. 2014 Nov 28;6:195-204
pubmed: 25506250
Br J Pharmacol. 2015 Jul;172(13):3189-93
pubmed: 25964986

Auteurs

Elena Lucarini (E)

Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA)-Pharmacology and Toxicology Section, University of Florence, Viale Gaetano Pieraccini, 6, 50139 Florence, Italy.

Elena Trallori (E)

Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA)-Pharmacology and Toxicology Section, University of Florence, Viale Gaetano Pieraccini, 6, 50139 Florence, Italy.

Daniele Tomassoni (D)

School of Biosciences and Veterinary Medicine, University of Camerino, Via Gentile III Da Varano, 62032 Camerino, Italy.

Francesco Amenta (F)

Section of Human Anatomy, School of Pharmacy, University of Camerino, Via Madonna delle Carceri 9, 62032 Camerino, Italy.

Carla Ghelardini (C)

Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA)-Pharmacology and Toxicology Section, University of Florence, Viale Gaetano Pieraccini, 6, 50139 Florence, Italy.

Alessandra Pacini (A)

Department of Experimental and Clinical Medicine, Anatomy and Histology Section, University of Florence, Largo Brambilla 3, 50134 Florence, Italy.

Lorenzo Di Cesare Mannelli (L)

Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA)-Pharmacology and Toxicology Section, University of Florence, Viale Gaetano Pieraccini, 6, 50139 Florence, Italy.

Classifications MeSH